Feasibility of ABO-incompatible living donor liver transplantation in the rituximab era.
Ikegami
Toru
T
Shirabe
Ken
K
Soejima
Yuji
Y
Taketomi
Akinobu
A
Maehara
Yoshihiko
Y
D000017:ABO Blood-Group System / Q000276:immunology; D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D001402:B-Lymphocytes / Q000187:drug effects; D001787:Blood Group Incompatibility; D065095:Calcineurin Inhibitors; D006801:Humans; D056724:Immunity, Humoral / Q000187:drug effects; D007275:Injections, Intravenous; D008099:Liver / Q000276:immunology / Q000601:surgery; D017114:Liver Failure, Acute / Q000517:prevention & control; D016031:Liver Transplantation / Q000276:immunology* / Q000379:methods* / Q000401:mortality / Q000523:psychology* / Q000592:standards; D019520:Living Donors / Q000523:psychology; D010507:Periodicity; D010951:Plasma Exchange; D000069283:Rituximab; D014180:Transplantation / Q000523:psychology; D016896:Treatment Outcome
D000017:ABO Blood-Group System; D058846:Antibodies, Monoclonal, Murine-Derived; D065095:Calcineurin Inhibitors; D000069283:Rituximab